The Senate Finance Committee held on Tuesday the third in a series of hearings on drug pricing in America, which focused on the role of pharmacy benefit managers. 
  
"PBMs negotiate with the drug companies, as well as pharmacies, to arrive at a price for a drug and its ultimate cost," said Committee Chairman Chuck Grassley, R-Iowa. "This system of private entities negotiating is what I envisioned as an author of the Part D program. I still believe this is absolutely the right approach. ... However, it's our duty to understand how the system is working today and what we can do to improve it." 
  
Ranking Member Ron Wyden, D-Ore., said, "PBMs are supposed to be negotiators who get better deals on prescription drugs for patients. What they are is middlemen who've raked in profits while drug prices have shot into the stratosphere. And as most people will tell you, there are already too many middlemen taking a cut in the American health care system." 
  
Testifying at the hearing were Steve Miller, M.D., executive vice president and chief clinical officer of Cigna; Derica Rice, executive vice president of CVS Health and president of CVS Caremark; William Fleming, segment president, health care services at Humana; John Prince, CEO of OptumRx; and Mike Kolar, interim president and CEO at Prime Therapeutics.

Related News Articles

Headline
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights yesterday held a hearing on surging drug prices and…
Headline
Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research…
Headline
The Department of Health and Human Services today withdrew requests for proposals on ways individuals could import prescription drugs from other countries…
Headline
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).    “America’s hospitals and health systems are…
Headline
Retail prices for 260 widely used brand-name prescription drugs last year increased by an average 2.9%, more than twice the general rate of inflation,…
Headline
The Campaign for Sustainable Rx Pricing (CSRxP), of which the AHA is a founding member, today launched new television and digital advertising encouraging…